6th March 2013
Place: Newcastle-upon-Tyne, UK.
Leica Biosystems introduces the Novocastra HD menu for dermatopathology, the third portfolio of antibodies for IHC in the new Novocastra HD range.
Each antibody has been independently assessed*...
Place: Newcastle upon Tyne
Leica Biosystems introduces new Novocastra HD antibody menu for Head and Neck Pathology
The Novocastra™ HD menu for head and neck pathology comprises six antibodies#, each selected following extensive customer...
Galena Biopharma and Leica Biosystems Announce Partnership to Develop Companion Diagnostic for HER2 Screening in Women with Breast Cancer
Leica Biosystems will develop a fully automated HER2 diagnostic to support identification of appropriate HER2...
Earlier this week, we participated in the 38th Annual National Society of Histotechnology (NSH) Convention under the new Leica Biosystems brand. Our presence included providing demonstration equipment for workshops, our experts hosting education...
Leica Microsystems announces the introduction of the Novocastra™ HD antibody range, 80 clinically important immunohistochemistry antibody clones, spanning 10 anatomical pathologies.
Newcastle Upon Tyne, England. Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Bond Oracle HER2 IHC System (Product Code TA9145) with the...
